(Q37844574)

24 August 2017

1 reference

title

Drug safety evaluation of ziprasidone (English)

1 reference

24 August 2017

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

19 February 2011

1 reference

Expert Opinion on Drug Safety

24 August 2017

published in

1 reference

24 August 2017

volume

10

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

437-448

1 reference

Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Using oral ziprasidone effectively: the food effect and dose-response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Ziprasidone-induced priapism requiring surgical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Torsade de pointes after ziprasidone overdose with coingestants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

QT prolongation and Torsades de Pointes following overdose of ziprasidone and amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

No significant QTc interval changes with high-dose ziprasidone: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Ziprasidone in the management of schizophrenia : the QT interval issue in context

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2011.560114

10.1517/14740338.2011.560114

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference